New eye drop for dry eyes enters safety testing
NCT ID NCT07593404
First seen May 29, 2026 · Last updated Jun 22, 2026 · Updated 6 times
Summary
This study tests a new lubricating eye drop called ABR2 in 40 adults with dry eye syndrome. The goal is to check if the drop is safe and tolerable when used for up to 28 days. Participants first receive a single drop in one eye, then use the drop at least twice daily for a month. This is an early-stage trial with no comparison group, so it focuses on side effects rather than effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE SYNDROME (DES) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre for Ocular Research & Education, School of Optometry & Vision Science, University of Waterloo
RECRUITINGWaterloo, Ontario, N2L 3G1, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABR2 (ocular lubricating eye drop)
What this could lead to
If successful, this could lead to a new over-the-counter option for temporary dry eye relief.
What could go wrong
This is a very early, small safety study with no placebo group, so it cannot prove the drop works better than existing products. Side effects like eye redness or allergy are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.